Furthermore, the utilization of IL15 in combination therapy with other cytokines (e.g. IL-21 or GMCSF), or co-stimulatory molecules (CD40) is a potential avenue to be explored to improve current cancer immunotherapy. The gene discussed is CD40; the disease is cancer.